Nanocapsules: A new type of lysosomotropic carrier

Couvreur, P.; Tulkenst, P.; Roland, M; Trouet, André; Speiser, P

doi:10.1016/0014-5793(77)80717-5

Cited by 170 publications

(51 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) were first described in 1977 8 and were recently the subject of a comprehensive review of their properties, preparation methods and potential therapeutic applications. 9 They are generally prepared from (iso)butylcyanoacrylate or (iso)hexylcyanoacrylate monomers by emulsion anionic polymerization in an acidic aqueous solution of a colloidal stabilizer such as dextran 70, polysorbates, and poloxamers.…”

Section: General Considerationsmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: General Considerationsmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…As a result, they are excellent drug carriers for a range of applications in sensing, imaging, and therapeutics [18]. The first type of polymers employed for the construction of nanoparticles were non-biodegradable, such as polyacrylamide or polymethylmethacrylate [19], and not applicable for administration in humans. The discovery of novel biocompatible polymers such as albumin [20] (a polyamide used to carry paclitaxel, marketed as Abraxane®), polyalkylcianoacrylate [21] (a polyanhydride), polylactateco-glycolate (PLG, a polyester that is FDA approved), solid lipid nanoparticles (SLN, produced using high-melting lipids) [22], chitosan (a hydrophilic and cationic polysaccharide obtained from crab shell) etc., opened the way for the clinical application, mostly in cancer treatment, of polymeric nanomaterials.…”

Section: Polymeric Nanomaterialsmentioning

confidence: 99%

Nanotechnology Advances in Drug Delivery

Velluto¹,

Ricordi²

2017

NanoWorld J

View full text Add to dashboard Cite

Drug delivery emerged as a discipline to solve problems associated with the majority of the current drugs, such as poor water solubility, poor physical stability, poor absorption and side effects. Large pharmaceutical companies are investing in drug delivery technologies to find better ways to administer existing drugs rather than designing new products. The secret to a successful drug delivery system, one that allows controlled release over a prolonged period of time, is in the carrier. An ideal drug carrier must be biocompatible, biodegradable, water friendly, selective, easy to prepare, stable, cheap, and finally, ultra-small. Therefore, the interdisciplinary field of nanotechnology and nanomaterials is playing a big role in drug delivery by providing new tools to develop ideal nanocarriers and find appropriate solutions for medical problems. In this review, we briefly recapitulate the history of nanomaterials in drug delivery, explore their unique properties, and report an example of the design and development of polymerbased nanomaterials. We also revisit the most challenging applications of drug delivery for cancer treatment, cell and tissue transplantations and stem cell therapies. Overall, nanotechnology-based drug delivery systems administered by different routes can be considered promising tools to improve patient compliance and achieve better therapeutic outcomes in critical illnesses.

show abstract

“…38 This is predicated on the fact that monodisperse nanomaterials are small enough to get into many substructures of organs like tissues, cells and even subcellular organelles which is the dawn of many unstable active molecules to cross the cell membrane. 39,40 The dawn also belongs to brain agent delivery to treat the malignant primary brain tumors. 41 Over the years, nanomaterials synthesized for malignant primary brain tumors have undergone several generations, from \naked" carriers to surfacemodi¯ed vectors and from monofunctional vehicles to multifunctional transporters.…”

Section: General Conceptsmentioning

confidence: 99%

The Application of Nanomaterials in Diagnosis and Treatment for Malignant Primary Brain Tumors

Liang

Fang

2014

NANO

View full text Add to dashboard Cite

Malignant primary brain tumors have a very high morbidity and mortality. Even though enormous advances have been made in primary brain tumor management, in the case of malignant primary brain tumors, current diagnostic strategies cannot identify exact in¯ltrating margins, surgery alone cannot achieve total mass resection, and adjuvant therapies cannot improve survivals. Therefore, there is an urgent need to explore novel strategies to diagnose and treat such in¯ltrating brain tumors. Nanomaterials, particularly zero-dimensional and one-dimensional platforms, can carry various compounds such as contrast agents, anticancer drugs and genes into brain tumor cells speci¯cally. Thus, contrast agent-based nanomaterials can selectively present in¯ltrating tumor outlines, while anticancer agent-based nanomaterials can speci¯cally kill malignant tumor cells. In addition, dual-targeting nanomaterials, multifunctional nanocarriers, theranostic nanovehicles as well as convection-enhanced delivery technology hold promise to increase drug accumulation in tumor tissues, which could largely improve anticancer e±cacy. In this review, we will mainly focus on the application of nanomaterials in preoperative diagnosis, intraoperative diagnosis and adjuvant treatment for malignant primary brain tumors.

show abstract

Nanocapsules: A new type of lysosomotropic carrier

Cited by 170 publications

References 7 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Nanotechnology Advances in Drug Delivery

The Application of Nanomaterials in Diagnosis and Treatment for Malignant Primary Brain Tumors

Contact Info

Product

Resources

About